CNW/ - Oppenheimer Holdings Inc. ("OPY") today announced that its principal operating subsidiary, Oppenheimer & Co. Inc. ("Oppenheimer"), reached an ...
Hosted on MSN
Oppenheimer confident in positive PROSERA trial readout in February 2026 for Gossamer Bio (GOSS)
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the stocks that will double in 2026. On December 9, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio, with a price target of $15.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results